siltuximab · Medicine question

How does siltuximab block interleukin-6 signalling?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Siltuximab forms high-affinity, stable complexes with soluble bioactive human interleukin-6 (IL-6), preventing its binding to soluble and membrane-bound IL-6 receptors and thereby inhibiting formation of the hexameric signalling complex with gp130 on the cell surface.

Sources for this answer

SYLVANT 100 mg powder for concentrate for solution for infusionRecordati UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 12Document updated 28 June 2024

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

Can siltuximab increase cholesterol and triglyceride levels?Has the safety and efficacy of siltuximab been established in children aged 17 years or younger?Have the effects of siltuximab on human fertility been evaluated?How long must women of childbearing potential use effective contraception after siltuximab treatment?What does Sylvant (siltuximab) powder for concentrate for solution for infusion look like before reconstitution?What was the most serious adverse reaction associated with siltuximab?

loading page…

Answer

Sources for this answer

More questions about siltuximab

Answer

Sources for this answer

More questions about siltuximab

siltuximab

More clinical questions?